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Edited by Gianni CesareniAbstract Recent realization of ligand-directed functional selec-
tivity demands high-resolution tools for studying receptor bio-
logy and ligand pharmacology. Here we use label-free optical
biosensor to examine the dynamic mass redistribution of human
epidermoid A431 cells in response to diverse b2-adrenoceptor
ligands. Multi-parameter analysis reveals distinct patterns in
activation and signaling of the receptor induced by diﬀerent ago-
nists. Sequential and co-stimulation assays categorize various
ligands for their ability to modulate signaling induced by cate-
chol, a structural component of catecholamines. This study
documents multiple ligand-speciﬁc states of the b2-adrenoceptor
and highlights the power of the biosensor assays for screening
pathway-biased ligands.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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G protein-coupled receptors (GPCRs) are the largest family
of cell membrane receptors and the richest class of drug targets
in the human genome. Classical receptor-occupancy theories
deﬁne the eﬃcacy of ligands as their ability to alter the equilib-
rium between inactive and active states of the receptor, assum-
ing that all GPCR activities are correlated [1]. However, the
recent data have challenged this simple kinetic model. Amass-
ing evidence suggests that GPCR signaling is sophisticated – a
receptor may couple simultaneously to more than one G pro-
tein subtype and interact with other signaling molecules such
as arrestins [2]. In many cases the activation of a receptor
can mediate both G protein-dependent and independent sig-
naling, often in a ligand-dependent manner [3–5]. As a result,
GPCRs display rich behaviors in cells, and many ligands can
induce operative bias to favor speciﬁc portions of the cell
machinery and exhibit pathway-biased eﬃcacies [6,7].
Given the signiﬁcance of ligand-directed functional selectiv-
ity in drug development [8], the possibility of a ligand havingAbbreviations: GPCR, G Protein-coupled receptor; b2AR, b2-Adreno-
ceptor; DMR, dynamic mass redistribution; RWG, resonant-wave-
guide grating; cAMP, cyclic adenosine monophosphate; DIPC,
dynamin inhibitory peptide; SPR, surface plasmon resonance; PWR,
plasmon-waveguide resonance
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doi:10.1016/j.febslet.2008.01.021multiple eﬃcacies demands high-resolution pharmacological
assays for screening pathway-biased ligands. It is obviously
diﬃcult in practice for conventional cell assays, which are
mostly pathway-biased and assay only a single signaling event
[9], to systematically represent the signaling potentials of
GPCR ligands [10]. Label-free optical biosensors including
surface plasmon resonance (SPR), resonant-waveguide grating
(RWG), and plasmon-waveguide resonance (PWR) are rou-
tinely used for biomolecular interaction analysis [11,12].
Recently, we had applied label-free optical biosensors for
whole cell sensing, and found that these biosensors are capable
of monitoring endogenous receptor activation, leading to high-
information and physiologically relevant measures of a recep-
tor–ligand pair [13–16]. These assays do not require prior
knowledge of cell signaling, and are pathway-unbiased [16].
The optical responses recorded are pathway-sensitive, and do
reﬂect the complexity of receptor signaling [13]. Thus, we
hypothesized that the biosensor-based cellular assay is amena-
ble to studying ligand-selective signaling. Here we examined
the functional selectivity of various ligands for endogenous
b2-adrenoceptor (b2AR) in A431 cells using the biosensor.
Results showed that there is a strong correlation between the
structures of ligands and the characteristics of their optical
signals.2. Methods
2.1. Materials
Alprenolol, cell preamble dynamin inhibitory peptide (DIPC),
CGP12177, dopamine, epinephrine, forskolin, ICI 118551, isoprotere-
nol, labetalol, norepinephrine, pindolol, S()pindolol, propranolol,
salbutamol, salmeterol, timolol, and xamoterol were obtained from
Tocris (St. Louis, MO). Catechol, halostachine, tyramine, and phenyl-
ethylamine were purchased from Sigma (St. Louis, MO). Cell culture
compatible Epic 384 well RWG biosensor microplates were obtained
from Corning Inc. (Corning, NY).2.2. Cell culture
Human epidermoid carcinoma A431 cells (American Type Cell Cul-
ture) were grown in Dulbeccos modiﬁed Eagles medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 4.5 g/l glucose,
2 mM glutamine, and antibiotics. 1.8 · 104 cells at passage 3–15 sus-
pended in 50 ll the medium containing 10% FBS were placed in each
well of a 384 well microplate, and were cultured at 37 C under air/5%
CO2 for 1 day, followed by 20 h starvation through continuously
culture in the serum-free DMEM.
2.3. Optical biosensor system and cell assays
Corning Epic wavelength interrogation system was used. This sys-
tem consists of a temperature-control unit, an optical detection unit,
and an on-board liquid handling unit with robotics. The detection unitblished by Elsevier B.V. All rights reserved.
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cellular responses with a time interval of 7 or 15 s.
The RWG biosensor exploits its evanescent wave, created by the to-
tal internal reﬂection of light at a solution–surface interface, to mea-
sure ligand-induced dynamic mass redistribution (DMR) signals in
cells. The evanescent wave extends into the cells and exponentially
decays over distance, leading to a characteristic sensing volume of
150 nm [15], implying that any optical response mediated through
the receptor activation only represents an average over the portion
of the cell that the evanescent wave is sampling. Such sampling with
the biosensor is suﬃcient to diﬀerentiate the signaling of distinct classes
of GPCRs in living cells, and oﬀers a simpliﬁed representation of
GPCR signaling [13,16,17].
Like SPR, the RWG biosensor is sensitive to refractive index – an
intrinsic property of biomolecules. Since the refractive index of a given
volume within a cell is largely determined by the concentrations of bio-
molecules such as proteins [18], we found, based on a three-layer wave-
guide grating theory, that a ligand-induced optical response is largely
associated with DMR [15]. The relocation of cellular targets towards
the sensor surface (e.g., relocation of intracellular targets to the acti-
vated receptors at the basal membrane surface) makes a positive con-
tribution to the DMR; conversely, the movement of cellular targets
away from the sensor surface (e.g., receptor internalization) is a nega-
tive contributor to the DMR. The aggregation of these events deter-
mines the kinetics and amplitudes of a ligand-induced DMR.
However, recent studies, using PWR technology and in vitro reconsti-
tuted GPCRs immobilized onto the sensor surface, showed that a
ligand-induced optical response of the receptor-lipid membrane system
consists of two components – changes in mass density and changes inFig. 1. The structures of b2AR ligands and their DMR in quiescent A431
(10 nM), norepinephrine (100 nM), dopamine (32 lM), halostachine (500 lM
salmeterol (8000 nM), salbutamol (164 nM), labetalol (2 lM), xamoterol (1 l
alprenolol (4 lM). The grey arrows indicated the time when the agonist wasstructure [12,19]. Since the RWG biosensor used here is unable to
diﬀerentiate the contributions of these components, ligand-induced
changes in organization of biomolecules in living cells may also con-
tribute to the overall response measured.
For biosensor cellular assays, a 2-min baseline was ﬁrst established,
compound solutions were then transferred into the sensor plate having
cells maintained in Hanks balanced salt solution (20 mM Hepes, pH
7.1), and the cell responses were recorded continuously. All studies
were carried out at controlled temperature (28 C) and with three rep-
licates for each measurement, unless speciﬁcally mentioned. The assay
coeﬃcient of variation was found to be <10%. All dose-dependent re-
sponses were analyzed using non-linear regression method with the
Prism software (Graph Pad).3. Results
3.1. Ligand-speciﬁc DMR signals
We chose the endogenous b2AR in A431 as a model system
for assaying ligand-directed functional selectivity with the bio-
sensor, because of its well-established signaling, and the avail-
ability of a rich source of structurally similar ligands having a
wide spectrum of eﬃcacies.
Fig. 1 graphically depicts the chemical structures and DMR
signals in quiescent cells of distinct ligands, whereas Table 1
summarizes their DMR characteristics. The b2AR ligand-cells. The ligands included ()epinephrine (8 nM), ()isoproterenol
), catechol (500 lM), tyramine (125 lM), phenylethylamine (500 lM),
M), pindolol (8 lM), S()pindolol (8 lM), CGP12177 (100 nM), and
introduced.
Table 1
The characteristics of b2AR ligands
Ligand logKi logEC50 ± S.E. P-DMR (pm) N-DMR (pm) s (s) t1/2 (s)
Isoproterenol 6.97 11.07 ± 0.07 232 ± 15 37 ± 5 130 ± 20 534 ± 32
Epinephrine 7.16 10.13 ± 0.06 232 ± 12 37 ± 7 132 ± 20 521 ± 25
Norepinephrine 5.40 7.99 ± 0.07 209 ± 16 29 ± 5 180 ± 17 559 ± 15
Dopamine 4.35 5.96 ± 0.06 214 ± 32 31 ± 4 252 ± 15 480 ± 23
Catachol 3.80 3.30 ± 0.07 152 ± 13 0 ± 3 130 ± 15 289 ± 42
Halostachine 5.08 4.63 ± 0.05 208 ± 21 20 ± 7 200 ± 32 349 ± 41
Salmeterol 8.89 9.68 ± 0.07 160 ± 14 0 ± 4 290 ± 17 370 ± 45
6.90 ± 0.10 244 ± 23 40 ± 11 152 ± 20 n.a.
Salbutamol 5.35 9.07 ± 0.04 209 ± 13 32 ± 3 132 ± 20 539 ± 32
Labetalol 7.97 8.05 ± 0.05 149 ± 17 8 ± 4 250 ± 15 544 ± 46
CGP12177 9.20 9.95 ± 0.07 123 ± 14 5 ± 5 238 ± 26 582 ± 32
Alprenolol 9.49 10.23 ± 0.09 124 ± 16 0 ± 4 233 ± 15 540 ± 26
S()pindolol 10.16 10.85 ± 0.06 137 ± 12 0 ± 3 249 ± 26 580 ± 56
Pindolol 9.15 9.97 ± 0.04 142 ± 19 0 ± 4 250 ± 15 516 ± 47
Xamoterol 6.06 7.32 ± 0.08 75 ± 18 0 ± 5 260 ± 26 974 ± 150
The binding aﬃnities were obtained from the GPCR ligand database (http://www.gpcr.org/7tm/ligand/ligand.html). The EC50 was calculated based
on the DMR response at the time point of 50 min. The t1/2 was calculated based on the ﬁtting of the P-DMR with a one-phase exponential
association non-linear regression.
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their dynamics. The ﬁrst group included isoproterenol, epi-
nephrine, norepinephrine, dopamine, halostachine, labetalol,
and salbutamol, each of which mediated a biphasic DMR re-
sponse. Following a small decrease in signal (termed as nega-
tive-DMR, N-DMR) with a short duration was an increased
signal (termed as positive-DMR, P-DMR) to an elevated level
with ligand-dependent maximal amplitudes and kinetics. The
second group included catechol, xamoterol, alprenolol,
CGP12177, S()pindolol, and pindolol, each of which medi-
ated an initial steady phase with a short duration, and a suc-
ceeding P-DMR. The third group included salmeterol.
Salmeterol induced a biphasic dose-dependent DMR (Fig. 2).
Salmeterol at low doses (<50 nM) induced a CGP12177-like
DMR, but at high doses an epinephrine-like DMR. The fourth
group included phenylethylamine and tyramine, both of which
induced a complicated DMR signal, possibly due to crosstalksFig. 2. The salmeterol-induced DMR. The inset showed two repre-
sentative DMRs induced by salmeterol of 10 nM and 1000 nM,
respectively.with another receptor(s) (see Supplementary material). Thus
both were excluded from further analysis. The ﬁfth group in-
cluded ICI 118551, propranolol, timolol, satolol, betaxolol,
and atenolol and CGP20712, none of which caused any signif-
icant DMR (data not shown). Given the sensitivity of the
DMR signals to signaling pathway involved [13,16], these re-
sults suggest that these ligands diﬀer greatly in their ability
to activate the b2AR and direct its signaling.3.2. Ligand-induced DMR are speciﬁc to the b2AR
Since A431 also naturally expresses other receptors [16], we
were interested whether the DMRs obtained are speciﬁc to the
b2AR. Results showed that the b-blocker propranolol dose-
dependently attenuated the DMR induced by all agonists at
their corresponding EC100, yielding similar IC50s (see Supple-
mentary material). Interestingly, dopamine of high doses
(>100 lM) led to a DMR that can only be partially inhibited
by 1 lM propranolol (see Supplementary material), suggesting
that the DMR of dopamine only at low doses is speciﬁc to the
b2AR. Thus, the following discussions were limited to dopa-
mine <100 lM. Nonetheless, these results suggest that the
ligand-induced DMRs are b2AR-speciﬁc.3.3. Ligand-speciﬁc eﬃcacy
Since these agonists exhibit diﬀerent capacities in activating
the b2AR, we were interested in their eﬃcacies based on DMR
measures. The maximal amplitudes of the P-DMR, normalized
to the epinephrine response, were in the following order:
isoproterenol (105%)  epinephrine (100%) > norepinephrine
(91%)  dopamine (92%)  salbutamol (91%)  halostachine
(90%) > catechol (66%)  alprenolol (65%)  labetalol (62%)
pindolol (61%)  S()pindolol (60%) > CGP12177 (54%) 
alprenolol (54%) > xamoterol (33%) (n = 16) (Table 1). A sim-
ilar but more pronounced trend was observed for the N-DMR
event. These results suggest that both isoproterenol and epi-
nephrine fully or nearly fully activate the b2AR, while the
other ligands partially activate the receptor.
3.4. Ligand-speciﬁc shift of apparent potency relative to aﬃnity
Many studies have shown that, similar to the eﬃcacy, the
ligand potency is also signal output-dependent; and the shifts
Fig. 3. The shifts in apparent DMR EC50 relative to binding aﬃnity of
the b2AR agonists. Fig. 4. The DMR signals of A431 cells induced by 2 nM epinephrine
without (control) and with the pretreatment with 25 lM dynamin
inhibitory peptide (DIPC-treated cells).
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the diﬀerential coupling eﬃciencies of ligands. Results showed
that all b2AR ligands induced a dose-dependent and saturable
response, yielding a single EC50 (see Supplementary material),
except for salmeterol which exhibited two well-separated EC50
values (0.12 ± 0.05 nM and 130 ± 17 nM) (Fig. 2). Because of
its biphasic dose responses, the potency of salmeterol shifted
in both directions (Fig. 3). In comparison, the EC50 of the
two full agonists, isoproterenol and epinephrine, signiﬁcantly
shifted towards the left. Similar shifts, but to lesser extent, were
observed for the three strong partial agonists, norepinephrine,
dopamine and salbutamol. Conversely, little shift was ob-
served for the other weak partial agonists that poorly activate
Gs. These results suggest that the weaker the agonist is, the clo-
ser to kd the EC50 is; and the greater shift in EC50 indicates that
the ligand is more eﬀective in causing cyclic adenosine mono-
phosphate (cAMP) accumulation.
3.5. Ligand-speciﬁc DMR kinetics
Since the DMR is a real-time kinetic cellular response, we
examined the kinetic characteristics of these b2AR ligand-
induced DMRs, including the transition time s for the
P-DMR event to occur. Ligands that caused a rapid transition
(s  140 s) included isoproterenol, epinephrine, salmeterol of
high doses, catechol and salbutamol. In comparison, all other
partial agonists including salmeterol of 10 nM resulted in a
slow transition (s  200–300 s).
Except for salmeterol at high doses, the P-DMR events
induced by all agonists seem to ﬁt well with a one-phase
exponential association, leading to a characteristic t1/2 (see
examples in Supplementary material; Table 1). Ligands that
are known to be ineﬀective or less eﬀective in causing receptor
internalization [20] resulted in a rapid P-DMR. These ligands
were dopamine, catechol, halostachine, and salmeterol of low
doses. Ligands that are known to be eﬀective to cause receptor
internalization resulted in a slow P-DMR with a t1/2 of 540 s;
these ligands were isoproterenol, epinephrine, norepinephrine,
and salbutamol. Interestingly, xamoterol induced the slowest
P-DMR.
The receptor internalization involves the relocation of the
activated receptor/eﬀector complexes away from the basal cell
membrane and is a negative contributor to the overall response
[15]. Thus, we speculated that the diﬀerentiated kinetics in theP-DMR may be related to internalization in part. Since dyn-
amin plays an important role in the ligand-induced b2AR
internalization [21], we examined the eﬀect of inhibiting dyn-
amin activity on the ligand responses. Results showed that
the pretreatment of cells with DIPC signiﬁcantly accelerated
the kinetics of the epinephrine P-DMR, leading to a t1/2 of
200 s (Fig. 4), suggesting that the receptor internalization
has negative impact on the kinetics of the epinephrine P-
DMR. Conversely, the DIPC pretreatment had little eﬀect
on the P-DMR induced by catechol or halostachine (data
not shown). Together, these results suggest that at least for cat-
echolamine agonists, the diﬀerence in P-DMR kinetics seems
to be an indicator for the ability of ligands to cause receptor
internalization.3.6. Catechol exhibits diﬀerent abilities to modulate b2AR
ligand-induced DMR
Catechol seems to be an eﬀective molecular probe to diﬀer-
entiate mechanistic diﬀerences between b2AR activation by
catecholamine agonists and by the structurally related non-cat-
echol partial agonist salbutamol [22]. Thus, we examined the
ability of catechol to modulate the DMR induced by other li-
gands. Results showed that the co-stimulation of A431 with
pindolol of 10 nM and catechol of 500 lM led to a DMR that
closely resembled, but was not identical to, the sum of the two
individual DMRs (Fig. 5a). The co-stimulated P-DMR exhib-
ited faster transition time and kinetics. Moreover, pindolol in
the presence of 500 lM catechol yielded an EC50 almost iden-
tical to pindolol alone (Fig. 5b). Similarly, other partial ago-
nists including alprenolol, CGP12177 and halostachine
resulted in an almost identical pattern (see Supplementary
material; data not shown). These results suggest that these par-
tial agonists do not directly compete with the binding of cate-
chol to the b2AR, and lead to signaling mostly independent of
the catechol-induced signaling. Conversely, the co-stimulation
of A431 with epinephrine or norepinephrine and 500 lM cate-
chol shifted the EC50 of either agonist to the right (Fig. 5b;
data not shown), indicating that catechol does directly com-
pete with both agonists; and either agonist can override the
catechol response with a cost of decreased potency. Together,
Fig. 6. The impact of b-blockers on the catechol (500 lM) response.
(a) The catechol response (control) was compared with those in cells
pretreated with 500 nM ICI 118551 or 10 nM propranolol. (b) The
catechol response (control) was compared with those in cells pretreated
with 1 lM SCH 23390, 500 nM CGP20712, or 250 nM sotalol.
Fig. 5. The eﬀect of catechol co-stimulation on the ligand-induced
DMR. (a) The DMR signals induced by 500 lM catechol (Catechol),
or 10 nM pindolol (Pindolol) were compared with that co-stimulated
with 500 lM catechol and 10 nM pindolol (Pindolol + Catechol). The
simple sum of both catechol and pindolol responses (Calculated) was
also presented. (b) The dose-dependent responses induced by pindolol
or epinephrine individually were in comparison with those induced by
co-stimulation of either ligand with 500 lM catechol.
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3.7. b-Blockers partially attenuate the catechol-induced DMR
We further examined the ability of several b-blockers to
modulate the catechol-induced DMR. The blockers were in-
verse agonists ICI 118551 and propranolol, and antagonists
timolol, sotalol, betaxolol, and atenolol. All these blockers
attenuated, but were unable to completely inhibit, the catechol
response (Fig. 6). Moreover, both ICI 118551 and propranolol
altered the dynamics of the catechol signal from a single
P-DMR to a Gq-like DMR [15,16,23]. Conversely, the other
b-blockers, but not SCH23390, simply suppressed in a dose-
dependent manner the amplitude and duration of the catechol
signal. The apparent IC50 was 1.8 ± 1.5 nM, 193 ± 23 nM,
46.0 ± 11.3 nM, 415 ± 32 nM, 5.8 ± 1.3 nM, 0.07 ± 0.04 nM,
and 12.7 ± 3.5 nM for propranolol, betaxolol, CGP20712,
atenolol, sotalol, timolol, and ICI 118551, respectively. These
results suggest that these b-blockers may not directly occupy
the catechol-binding pocket, but do impact the catechol down-
stream signaling.4. Discussion
The b2AR signaling involves a series of orderly spatial and
temporal events, many of which contribute to a ligand-induced
DMR. Thus, it is diﬃcult to link speciﬁc cellular events to the
DMR. Here we primarily used multi-parameter-based pattern
analysis, and discussed the functional selectivity of various
ligands in the context of known characteristics of b2AR signal-
ing. The agonists examined diﬀer greatly in their abilities to
cause cAMP accumulation, receptor internalization and/or
interaction with b-arrestin. Their functional selectivity is
clearly evident in DMR characteristics.
Epinephrine, isoproterenol, norepinephrine and dopamine
are structurally similar catecholamine agonists, all of which
led to a similar type of DMR, characterized by the occurrence
of the N-DMR (Fig. 1). All four ligands are known to produce
comparable cAMP through the b2AR, but diﬀer greatly in
causing receptor internalization [20,24]. Conversely, catechol
was unable to produce an epinephrine-like DMR – there is
no N-DMR event in the catechol response. Catechol is a very
weak partial agonist to activate Gs, leading to very small
increase in cAMP but not receptor internalization [22].
These results suggest that the occurrence of the N-DMR is
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lar cAMP level.
For the four catecholamine agonists, their P-DMR exhibited
clearly diﬀerent kinetics. The inhibition of dynamin activity
signiﬁcantly accelerated the kinetics of the epinephrine P-
DMR, but not the catechol response (Fig. 4). Furthermore,
both dopamine and catechol that are not eﬀective in causing
receptor internalization induced a faster P-DMR, compared
to the other three catecholamines. These results suggest that
the receptor internalization contributes negatively in part to
the P-DMR, and is hidden behind other cellular events that
occur simultaneously but cause increase in local mass density
(possibly an increase in cell adhesion; data not shown). The
delicate balance between them governs the apparent kinetics
of the P-DMR. Thus the P-DMR kinetics indicates the ability
of ligands to induce receptor internalization.
Halostachine also induced an epinephrine-like DMR
(Fig. 1). Halostachine was shown to cause a maximal increase
in cAMP at the whole cell level that was 20% of that induced
by epinephrine [20,22]. Since the cAMP produced due to the
b2AR activation is much restricted initially in some microdo-
mains in cells [25], the halostachine response suggests that
the threshold of localized cAMP resulting in the N-DMR
occurrence is relatively small, and/or halostachine is eﬀective
to cause localized cAMP production, but not at the whole cell
level. Interestingly, consistent with the poor ability of halosta-
chine to cause receptor internalization is that its P-DMR is
also rapid.
Salbutamol, salmeterol and labetalol are three structurally
related non-catechol ligands. These ligands exhibited great dif-
ference in mediating DMR signals. Salbutamol, the strong par-
tial agonist in activating Gs, induced an epinephrine-like
DMR. Labetalol induced a DMR in-between the catechol
and epinephrine responses, with a small but noticeable N-
DMR. Interestingly, salmeterol at low doses led to a labeta-
lol-like DMR, while salmeterol of >100 nM caused a salbuta-
mol-like DMR. Salmeterol is a long acting b-agonist with low
intrinsic activity, and exhibits dual eﬃcacies – a weak partial
agonist for producing an eﬀective interaction between the
receptor and b-arrestin 2, and a full agonist for causing cAMP
accumulation [26,27].
The four structurally related b-blockers alprenolol,
CGP12177, S()pindolol and pindolol all led to a catechol-like
DMR, but with distinct kinetics. CGP12177 is a partial agonist
of the b2AR, and is capable of stimulating Gs and causing
receptor internalization [28]. The co-stimulation with pindolol
and catechol induced a DMR being close to the sum of the two
DMRs obtained independently, and catechol did not alter the
EC50 of pindolol. A similar behavior was also observed for the
other three ligands. In contrast, the presence of catechol
shifted the EC50 of epinephrine or norepinephrine to the right.
These results suggest that these partial agonists do not com-
pete with the binding of catechol, and mediate signaling mainly
independent of catechol.
The other structurally diverse b-blockers led to no or little
DMR. However, these b-blockers were able to attenuate the
catechol response, with a maximal inhibition of 55%. The
catechol responses in the propranolol- and ICI 118551-pre-
treated cells were similar, but were diﬀerent from the cells pre-
treated with the other b-blockers (Fig. 6). These results were
surprising. A recent in vitro biophysical study showed that
ICI 118551 has little eﬀect on the catechol-induced ﬂuores-cence changes of a ﬂuorescently engineered b2AR, suggesting
that ICI 118551 is unable to inhibit the catechol-induced recep-
tor activation [22]. However, these studies were based on the
changes between only two points within an engineered recep-
tor, and their functional consequences were largely limited to
certain cellular events. Nonetheless, the present study suggests
that these b-blockers may not directly compete with catechol,
but do impact the catechol signaling through unknown mech-
anism(s).
In summary, we have used non-invasive optical biosensor to
study the functional selectivity of diverse b2AR ligands. Multi-
parameter analysis uncovers distinct patterns linking the struc-
ture to the ability of these ligands to mediate distinct receptor
signaling. The data presented here clearly demonstrates biased
agonisms of various b2AR ligands, and illustrates the power of
optical biosensors for probing ligand-directed functional selec-
tivity. However, there are still many unanswered questions –
which pathways are involved in the DMR and how these path-
ways are regulated in a ligand-speciﬁc manner, and whether
these pathways proceed collectively or independently. Further-
more, contributions from many cellular responses mediated
through a receptor that make the biosensor cellular assays so
valuable, however, also render the optical signal obtained
‘‘non-speciﬁc’’ relative to conventional cellular assays. Further
functional genomics and cell biology studies are in progress to
depict the nature of DMR signals mediated through the activa-
tion of GPCRs, including the b2AR.Appendix A. Supplementary material
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.
2008.01.021.
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